Press Releases

October 28, 2025 Governor Murphy and Local Leaders Attend Ribbon-Cutting Ceremony, Marking the Inauguration of Lupin’s New Corporate Offices in Bridgewater

October 24, 2025 Lupin Launches Authorized Generic Version of Ravicti® in the United States

October 13, 2025 Lupin Announces Presentation of Phase 1 Data on LNP3693 (STING agonist) at the ESMO Congress 2025

October 9, 2025 Lupin Unveils Strategic Partnership Program to Expand Reach of its Long-Acting Injectable Platform

October 8, 2025 Lupin Announces  Plans to Build a  New  State-of-the-Art  Manufacturing  Facility in Coral Springs, Florida  Extending its Long-Standing Commitment to America’s Patients and Healthcare System  

October 3, 2025 Lupin Launches Liraglutide Injection in the United States

October 1, 2025 Lupin Launches Rivaroxaban for Oral Suspension in the United States

September 30, 2025 Lupin Receives Approval from U.S. FDA for Rivaroxaban for Oral Suspension

September 29, 2025 Lupin Strengthens its Global Specialty Ophthalmology Business with Acquisition of VISUfarma from GHO Capital